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Bacterial signaling systems such as protein kinases and quo-
rum sensing have become increasingly attractive targets for the
development of novel antimicrobial agents in a time of rising
antibiotic resistance. The family of bacterial Penicillin-binding-
protein And Serine/Threonine kinase-Associated (PASTA)
kinases is of particular interest due to the role of these kinases in
regulating resistance to -lactam antibiotics. As such, small-
molecule kinase inhibitors that target PASTA kinases may
prove beneficial as treatments adjunctive to -lactam therapy.
Despite this interest, only limited progress has been made in
identifying functional inhibitors of thePASTAkinases that have
both activity against the intact microbe and high kinase speci-
ficity.Here, we report the results of a small-molecule screen that
identified GSK690693, an imidazopyridine aminofurazan-type
kinase inhibitor that increases the sensitivity of the intracellular
pathogen Listeriamonocytogenes to various-lactams by inhib-
iting the PASTA kinase PrkA. GSK690693 potently inhibited
PrkA kinase activity biochemically and exhibited significant
selectivity for PrkA relative to the Staphylococcus aureus
PASTA kinase Stk1. Furthermore, other imidazopyridine ami-
nofurazans could effectively inhibit PrkA and potentiate -lac-
tam antibiotic activity to varying degrees. The presence of the
2-methyl-3-butyn-2-ol (alkynol) moiety was important for both
biochemical and antimicrobial activity. Finally, mutagenesis
studies demonstrated residues in the back pocket of the active
site are important forGSK690693 selectivity. Thesedata suggest
that targeted screens can successfully identify PASTA kinase
inhibitors with both biochemical and antimicrobial specificity.
Moreover, the imidazopyridine aminofurazans represent a fam-
ily of PASTAkinase inhibitors that have the potential to be opti-
mized for selective PASTA kinase inhibition.
Antibiotics, in particular the -lactams, are considered one
of the greatest medical advances of the 20th century since their
discovery andwidespread use in the 1940’s (1). However, due to
themisuse of these life-saving drugs, antibiotic-resistant strains
of bacteria such as carbapenem-resistant Enterobacteriaceae
(CRE), vancomycin-resistant Enterococcus (VRE), and methi-
cillin-resistant Staphylococcus aureus (MRSA) are emerging at
an alarming rate (2, 3). The rapid evolution of resistance to
available antibiotics currently outpaces the rate of development
of new, effective treatments and highlights the need for the
development of truly novel antimicrobial strategies (4, 5). One
new strategy is the pursuit of novel compounds that target
microbial signaling cascades that are relatively overlooked by
traditional methods of antibiotic development. Reversible pro-
tein phosphorylation by bacterial kinases is one such process
that has been garnering attention within the past decade as a
potential target for truly novel antibiotics (6, 7).
Prokaryotic protein phosphorylation was originally thought
to occur predominantly on histidine and aspartate residues phos-
phorylated by two-component systems in a fashion distinct
from eukaryotic kinases (8, 9). However, since the discovery of
pkn1, a bacterial serine/threonine kinase with high structural
homology to eukaryotic protein kinases (10), genomic studies
have shown eukaryotic-like serine/threonine kinases (eSTKs)3
to be near ubiquitous in bacteria (11). Specifically,many impor-
tant Gram-positive pathogens have transmembrane eSTKs
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known as Penicillin-binding-protein And Ser/Thr kinase-As-
sociated (PASTA) kinases (12). In a variety of different patho-
gens, PASTA kinases have been found to regulate cell wall
homeostasis (13–17), germination (18, 19), metabolism (20,
21), biofilm formation (22), and virulence (23–32). The PASTA
kinase PknB is essential inMycobacterium tuberculosis (26, 33),
whereas genetic deletion of homologs in other species has been
linked to increased susceptibility to -lactam antibiotics (13,
24, 25, 34). These phenotypes have led to interest in PASTA
kinases as potential antibiotic targets in pathogens ranging
from M. tuberculosis and S. aureus to Listeria monocytogenes.
As a proof of principle, we previously demonstrated that phar-
macologic inhibition of the PASTA kinase PrkA by the nonspe-
cific kinase inhibitor staurosporine increases the susceptibility
of the intracellular pathogen L. monocytogenes to -lactams in
broth culture (34); however, staurosporine’s high promiscuity
among eukaryotic kinases makes it remarkably toxic and
undermines its usefulness as a candidate for therapeutic devel-
opment (35). Staurosporine’s hallmark toxicity highlights the
necessity for kinase inhibitors that are selective for a limited
number of targets.
Extensive efforts have been put forth to probe the biochem-
istry of eukaryotic kinases and identify structural features that
can be exploited by selective kinase inhibitors for the treatment
of a variety of human diseases, most notably cancer (36). Such a
wealth of established knowledge can be harnessed to probe bac-
terial kinase biochemistry and engineer inhibitors that act as
selective antibiotics. Furthermore, the abundance of available
small molecule kinase inhibitor libraries can be mined for
bacterial kinase-selective scaffolds. Here, we report that
GSK690693, an imidazopyridine aminofurazan (IPA) identified
in a small molecule kinase inhibitor library, sensitizes L. mono-
cytogenes to various -lactams. We show that other members
of the IPA family inhibit PrkA biochemically and sensitize
L. monocytogenes to -lactams to varying degrees. Finally, we
demonstrate selectivity for the L. monocytogenesPASTAkinase
both at the biochemical and microbiological level as compared
with the S. aureus PASTA kinase Stk1 on an amino acid level.
Taken together, our data validate the potential to exploit
PASTA kinases as druggable targets and establish GSK690693
and other IPAs as both lead compounds and valuable tools to
investigate PASTA kinase biology.
Results
GSK690693 sensitizes Listeria to-lactam antibiotics
In a wide variety of important Gram-positive pathogens,
PASTA kinases are essential for resistance to -lactam antibi-
otics (13, 25, 34). We have previously demonstrated that either
genetic deletion or pharmacologic inhibition of the PASTA
kinase PrkA with staurosporine sensitizes L. monocytogenes to
-lactams (34). To identify specific (and therefore potentially
less toxic) inhibitors of PrkA, we screened 625 small molecule
kinase inhibitors from the GlaxoSmithKline Published Kinase
Inhibitor Set (PKIS) (37, 38) and Selleck kinase inhibitor librar-
ies against wild-type L. monocytogenes strain 10403s in the
presence of a sublethal dose of the -lactam ceftriaxone (Fig.
1A). Sixteen compounds potentiated inhibition of L. monocyto-
genes growth by ceftriaxone at 3 S.D. or more above the mean
including the positive control staurosporine (Fig. 1A, blue dot).
Of these, nine compounds failed to show a dose-response, and
an additional three showed -lactam independence in second-
ary screens. The four remaining validated compounds were
LY2228820, GSK690693, and our previously published com-
pounds staurosporine and AZD5438 (supplemental Fig. S1).
We selected GSK690693 (Fig. 1, A, green dot, and B) for further
analysis due to the presence of structural congeners in the
screen (Fig. 1A, red dots).
Based on our previous investigation of staurosporine, we
hypothesized that GSK690693 would also sensitize L. monocy-
togenes to other -lactam antibiotics. To test this hypothesis,
we determined the minimal inhibitory concentration (MIC)
values of various antibiotics against wild-type L. monocytogenes
in the presence and absence of 20 M GSK690693 (Table 1).
Importantly, GSK690693 sensitized L. monocytogenes to other
-lactams as well, including ceftriaxone, ampicillin, and mero-
penem, but had no -lactam-independent effects up to 20 M
(supplemental Fig. S2), consistent with the lack of -lactam-
independent growth defects in prkA mutants (34). Although
GSK690693 had no effect on the MIC values of the non--
lactams vancomycin or kanamycin, it did sensitize L. monocy-
togenes to the TarO inhibitor tunicamycin, consistent with the
role of PASTA kinases in resistance to tunicamycin (23, 39). To
Figure 1. Library screen identifies GSK690693 as a compound that sen-
sitizes L. monocytogenes to ceftriaxone. A, scatter plot representing per-
cent growth inhibition ofWT L. monocytogenes in the presence of a combina-
tion of a sublethal dose (1 g/ml) of the -lactam ceftriaxone and each
compound in the screen. The solid black line represents the library mean (),
and the dashed black line and gray line represent two (2) and three (3) S.D.
above the library mean, respectively. The cyan, green, and red data points
represent staurosporine, GSK690693, and other compounds from the IPA
family, respectively. B, skeletal structure of GSK690693.
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confirm that GSK690693 potentiation of -lactam and tunica-
mycin sensitivity was through PASTA kinase inhibition, we
tested the sensitivity of the prkA mutant to the same antibi-
otics in the presence and absence of 20 M GSK690693.
GSK690693 afforded the prkA strain no additional sensitiza-
tion to any antibiotic tested, suggesting that the activity
of GSK690693 is PrkA kinase-dependent (Table 1). Finally,
GSK690693 sensitized wild-type L. monocytogenes in a concen-
tration-dependent manner to a fixed subinhibitory concentra-
tion of ceftriaxone, demonstrating the reciprocal dose depen-
dence of the kinase inhibitor--lactam potentiation (Fig. 2).
Taken together, our data demonstrates that GSK690693 sensi-
tizes L. monocytogenes to -lactam antibiotics through PrkA
inhibition.
GSK690693 inhibits PrkA in vitro
To assess the basis of kinase inhibitor/-lactam potentiation
at the biochemical level and to begin to understand biochemical
determinants of activity, we assessed the kinase activity of the
purified kinase domain of PrkA in the presence of increasing
concentrations of GSK690693. Analysis by autoradiography
revealed that GSK690693 robustly inhibited both PrkA autophos-
phorylation and phosphorylation of the nonspecific phospho-
acceptor myelin basic protein (MBP) at concentrations as low
as 2M (Fig. 3A). Consistent with this finding, analysis of kinase
inhibition in the Kinase-Glo assay (Promega) resulted in a
calculated IC50 value of 0.84 M (Table 2). Finally, in silico
docking of GSK690693 in the kinase domain of PrkA predicted
the 2-methyl-3-butyn-2-ol (alkynol) moiety penetrating into
the gatekeeper-guarded back pocket of the kinase active site,
similar to the orientation and mechanism of inhibition previ-
ously reported for GSK690693 bound to the eukaryotic kinase
AKT (Fig. 3B) (40). Taken together, our data demonstrate that
GSK690693 can directly inhibit PrkA activity in vitro.
Various IPAs display biochemical andmicrobiologic activity
There were seven other members of the IPA family in our
library screen (Fig. 1, red dots), three of which demonstrated
potentiation with ceftriaxone at 2 S.D. above the mean of
the screen and whose structures are shown in Table 3. To
determine whether the IPAs represent a broadly applicable
scaffold for PASTA kinase inhibitors we tested 3 additional
compounds for biochemical activity and ceftriaxone poten-
tiation: GSK554170A, GSK614526A, and GSK902056A (Fig.
4A, Table 2). All three compounds showed statistically similar
biochemical activity to GSK690693; however, GSK554170A
was 2-fold less potent than GSK690693 microbiological-
ly, whereas GSK614526A was 4-fold more potent than
GSK690693. Taken together, our data suggest that these varia-
tions in the R2 and R3 positions of the PIA scaffold may play a
role in target accessibility and/or stability in the bacterial cyto-
sol. In contrast, SB-747651A, an IPA that lacks the alkynolmoi-
ety, neither potentiated-lactam sensitivity (Fig. 4A) nor inhib-
ited biochemical activity (Fig. 4B). This is consistent with
molecular modeling that implicates the alkynol moiety in sta-
bilization of binding and kinase inhibition (Fig. 3B). Taken
together, our findings demonstrate thatmultiple compounds of
the IPA family are capable of augmenting ceftriaxone activity to
varying degrees and further suggest that the IPA pharmacoph-
ore can be further optimized for -lactam sensitization.
GSK690693 displays selectivity for PrkA over Stk1
AsPASTAkinases are highly conserved in a variety of impor-
tant human pathogens, we hypothesized that GSK690693 may
act on other PASTA kinases as well. Surprisingly, we observed
that GSK690693 was significantly less potent against the puri-
fied kinase domain of Stk1, the PASTA kinase homolog from
Staphylococcus aureus (Fig. 5A), with a predicted IC50 greater
than 40 M by a Kinase-Glo assay (supplemental Fig. S3E).
Consistent with this finding, neither the ceftriaxone nor oxacil-
lin MIC for the methicillin-resistant S. aureus strain LAC was
altered in the presence of GSK690693, although there was a
reproducibly minor slowdown in growth in the presence of
GSK690693 relative to antibiotics alone (supplemental Fig. S3,
Figure2.GSK690693potentiates the inhibitoryactionof ceftriaxone ina
dose-dependent manner. Growth curves of WT L. monocytogenes grown in
the presence of 2.5 g/ml of ceftriaxone and increasing concentrations (M)
of GSK690693. Curves are representative of 3 independent trials.
Table 1
MIC of various antibiotics against WT andprkA strains/ 20M GSK690693
Data presented as median of at least three biological replicates with the range in parentheses.
MIC (g/ml)
10403s prkA
GSK690693    
Ceftriaxone 8 (4, 8) 1 (0.5, 1) 0.0625 (0.03125, 0.25) 0.0625 (0.03125, 0.25)
Ampicillin 0.25 (0.25, 0.25) 0.0625 (0.0625, 0.125) 0.03125 (0.03125, 0.03125) 0.03125 (0.03125, 0.03125)
Meropenem 0.25 (0.25, 0.25) 0.125 (0.125, 0.25) 0.03125 (0.03125, 0.0625) 0.0625 (0.0625, 0.0625)
Tunicamycin 32 (32, 32) 0.5 (0.5, 1) 0.5 (0.5, 1) 0.5 (0.5, 1)
Vancomycin 2 (2, 4) 2 (2, 4) 1 (1, 1) 1 (1, 1)
Kanamycin 8 (8, 8) 8 (8, 8) 8 (8, 8) 8 (8, 8)
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D and E) consistent with the low level inhibition of Stk1
observed biochemically. In contrast, stk1 mutants are
potently sensitized to both -lactam antibiotics (Supplemental
Fig. S3, B andC) as previously described (24). Importantly, Stk1
can be biochemically inhibited by the kinase inhibitor indiru-
bin-3-monoxime, which shows relative selectivity for Stk1
over PrkA (supplemental Fig. S4). Consistent with this, three
recent papers have identified small molecule inhibitors of Stk1
that are structurally distinct from the IPAs we identified as
PrkA inhibitors (41–43). These data suggest that GSK690693
selectively inhibits the kinase activity of PrkA relative to Stk1
and highlight the possibility of designing non-broad spectrum,
pathogen-specific inhibitors.
Intrigued by the divergent activity against the two kinase
domains, we utilized in silico modeling to identify potential
structural deviations that might explain the selectivity. Exami-
nation of the back pockets of the Stk1 and PrkA kinase domains
revealed high sequence conservation with only four divergent
residues: Ser62(Stk1)/Ala63(PrkA), Met73/Val74, Leu85/Ile86,
and Phe150/Thr151 (Fig. 5B). As Phe150 and Thr151 sit at the
entrances of their respective kinase’s back pocket just upstream
of the catalytic DFG motif, we hypothesized that a bulky
“xDFG” residue at this position (such as Phe150 in Stk1) may
deny GSK690693’s alkynol group access to the pocket, whereas
a smaller residue (such as Thr151 of PrkA) may be permissible.
However, when these residues are swapped between kinases,
we found that PrkA T151F has greatly reduced intrinsic kinase
activity (supplemental Fig. S5), whereas Stk1 F150T sensitivity
to GSK690693 is unaffected (Fig. 5C). Alternatively, the three
other divergent residues (Met73/Val74, Leu85/Ile86, and Ser62/
Ala63) might alter the size and polarity of the pocket in a way
Figure 3. GSK690693 inhibits the PrkA kinase domain in vitro. A, autoradiography blot of purified PrkA kinase domain from L. monocytogenes and the
nonspecific phosphoacceptor substrate MBP in the presence or absence of GSK690693. Blot is representative of 3 independent trials. B (top), GSK690693
docked in silico into the threadedmodel of the kinase domain of PrkA (bottom) crystal structure of GSK690693bound to humanAKT (PDB ID 3d0e). Gatekeeper
methionine and xDF residues are represented as sticks.
Table 2
Summary of biochemical and microbiology data for various IPAs
against L. monocytogenes
Compound Relative IC50 (95% CI) Ceftriaxone MIC
M g/ml
DMSO NAa 8
GSK690693 0.84 (0.34, 2.00) 1
GSK554170A 0.45 (0.080, 2.49) 2
GSK614526A 0.42 (0.010, 17.17) 0.25
GSK902056A 0.41 (0.10, 1.63) 1
SB-747651A NA 8
a NA, not applicable.
Table 3
Structures of various IPA family compounds
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that generates selectivity. Strikingly, an Stk1 S62A/M73V/L85I
triple mutant is more sensitive to GSK690693 relative to the
wild-type kinase domain (Fig. 5C), although there is also a
minor decrease in intrinsic kinase activity. Overall, our data
suggests that, at least in part, selectivity of GSK690693 for PrkA
over Stk1 is not due to the xDFG residue but rather is mediated
by the size and charge of the back pocket that stabilizes the
alkynolmoiety facilitating inhibition. Additional pointmutants
altering the character of the back pocket in addition to synthe-
sizing alkynol modifications will help to establish a formal SAR
and may instruct the rational design of species-specific kinase
inhibitors in the future.
Discussion
Eukaryotic kinases have been a target of the pharmaceutical
industry for decades owing to their central role in a variety of
cancers and other diseases (44, 45). As of 2015, 27 protein
kinase inhibitors are FDA-approved for use in the clinic (46). In
light of this relative success in eukaryotes, prokaryotic protein
kinases have begun to be investigated as potentially novel anti-
biotic targets. A highly conserved family of bacterial kinases,
the PASTA kinases, have high levels of conservation with
eukaryotic kinases and play central roles in processes ranging
from metabolism and basic bacterial physiology to regulation
of virulence and -lactam antibiotic susceptibility. As such,
efforts are being put forth to identify small molecule inhibitors
of the PASTA kinases (34, 42, 47, 48). As these efforts progress,
it will be important to consider the need for a better under-
standing of the biochemistry of PASTA kinase inhibition to aid
in the development of selective kinase inhibitors.Here, we pres-
ent GSK690693 and other IPAs as novel inhibitors of the
L. monocytogenes PASTA kinase PrkA and as a tool to better
understand PASTA kinase biochemistry.
We identified 16 compounds, including GSK690693, which
inhibited growth of L. monocytogenes in the presence of a sub-
lethal dose of a -lactam by performing a small (625 com-
pound) primary screen of compounds known to possess a
pharmacophore with kinase-inhibiting attributes. We chose
GSK690693 above others due to its dependence on PrkA, its
dependence on the presence of a -lactam, and its dose depen-
dence. Although several inhibitors with PrkA-specific activity
may have been missed in our screen, the utilization of a micro-
biological screen rather than a biochemical screen immediately
overcame a significant barrier that has been encountered in
screens to identify M. tuberculosis PknB inhibitors, namely
identification of compounds capable of entering into the bac-
terium (47).
Seven congeners of GSK690693 were also present in our
screen, each possessing the characteristic alkynol moiety and
IPA scaffold but varying in the position and molecular struc-
tures of their respective side chains. Those thatwe further char-
acterized all had statistically similar IC50 values although their
microbiologic activity varied. This suggests a varying ability of
these compounds to access their target in the bacterial cytosol
or a difference in stability once in the cytosol, further exempli-
fying the need tomodify “Lipinski’s rule of 5” to account for the
bacterial cell wall when performing antibiotic development.
Our data indicate that modifications to the R2 or R3 position
may be more important in dictating target accessibility rather
than biochemical activity.
GSK690693’s eukaryotic SAR has established that the
alkynolmoiety penetrates into AKT’s gatekeeper-guarded back
Figure 4. IPAs potentiate ceftriaxone activity to varying degrees. A, dose-response curves of L. monocytogenes growth versus ceftriaxone in the presence
and absence of 10M IPAs. Curves are representative of 3 independent trials. B, autoradiography blot of purified PrkA kinase domain andMBP in the presence
or absence of GSK690693 or SB-747651A. The blot is representative of 3 independent trials.
Figure 5. Residues of the back pocket play a role in GSK690693 selectiv-
ity.A, autoradiographyblot of purified Stk1 kinasedomain from S. aureus and
MBP in the presence or absence of GSK690693. B, stick figure representation
of the amino acids that constitute the back pocket of the PrkA (cyan) and Stk1
(violet) kinase domains. GSK690693 (green sticks) is docked into the back
pocket, which is represented by the translucent cavity surface. C, autoradiog-
raphy blot of purifiedWT Stk1, F150Tmutant, S62A/M73V/L85I triplemutant,
andMBP in thepresenceor absenceofGSK690693. Blots are representativeof
3 independent trials.
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pocket to stabilize binding (40). Interestingly, SB-747651A is
completely unable to inhibit PrkA activity and sensitize
L. monocytogenes to a -lactam, likely due to the lack of the
alkynol moiety on the IPA scaffold. Although effects of
SB-747651A’s R2 side chain cannot be ruled out, it is worth
noting that all other tested IPAs that possess the alkynolmoiety
have some efficacy againstL. monocytogenesPrkA, regardless of
the side chain structure at R1 or R2.
Due to an expansion in our knowledge of the effects of cur-
rent antibiotics on the human microbiome (50, 51), one of the
challenges of antimicrobial development has become finding
antimicrobial compounds that are selective for the pathogen of
interest without disruption of normal microbiota or collateral
resistance effects. Therefore, we were intrigued to find that
GSK690693 showed selectivity for the PrkAkinase domain over
Stk1, the PASTA kinase from S. aureus that shows 49% identity
with PrkA across its kinase domain (Figs. 3A and 5A). PASTA
kinase inhibitors with varying degrees of biochemical activity
have been identified forM. tuberculosis PknB (19, 33, 47, 48, 52,
53), Enterococcus faecalis IreK (54), Bacillus subtilis PrkC (18),
L. monocytogenes PrkA (34), and staphylococcal Stk1 (22,
41–43); however, this work is the first to investigate the selec-
tivity of an inhibitor between two PASTA kinases. Given the
importance of the gatekeeper-guarded back pocket in the
eukaryotic SAR of GSK690693, we investigated differences in
the back pockets of PrkA and Stk1. Mutation of the most obvi-
ous amino acid residue (Stk1 F150T) at the entrance to the
pocket did not alter selectivity; however, mutation of the three
divergent residues that contribute to the shape and depth of the
back pocket profoundly affected the sensitivity of Stk1 to
GSK690693 (Fig. 5C). To our knowledge, investigations in
human kinases have not implicated these internal residues as
contributing to selectivity (55, 56). GSK690693 has been well-
established as relatively selective among eukaryotic kinases for
isoforms of AKT (38, 40, 57), although this is the first time
activity against specific bacterial kinases has been shown.Over-
all, GSK690693’s selectivity between two highly similar kinases
found in L. monocytogenes and S. aureus extends the concept
that pathogen-specific inhibitors could be identified and devel-
oped (34).
The mechanism by which PrkA mediates tunicamycin resis-
tance remains unknown. At low (non-lethal) concentrations,
tunicamycin inhibits the activity of TarO, the enzyme required
for the transfer of GlcNAc-1-phosphate from UDP-GlcNAc to
undecaprenyl phosphate during wall teichoic acid synthesis
(58). However, at higher (lethal) concentrations, tunicamycin
also blocks the activity of MraY, the essential enzyme required
for the transfer of phospho-MurNAc-pentapeptide to undeca-
prenyl phosphate during peptidoglycan synthesis (59). Sensiti-
zation to tunicamycin through PrkA inhibition may be due to
PrkA-mediated regulation of one or both of these proteins
directly as substrates. Alternatively, PrkA may act on the path-
ways further upstream or downstream of these proteins. Addi-
tionally, it is unknown why treatment with GSK690693 can
achieve the maximum-expected sensitivity to tunicamycin (i.e.
match the phenotype of a prkA mutant) but cannot do the
same for the -lactams. It is possible that the tunicamycin phe-
notype is dependent solely on kinase activity, whereas the
-lactam phenotype might be dependent on both kinase activ-
ity and other non-enzymatic roles of PrkA. If true, then inhibi-
tion of kinase activity by GSK690693 would only be able to
achieve a fraction of the phenotype of the genetic deletion.
Determining if there are kinase activity-independent functions
of PrkA is an active area of investigation.
As with tunicamycin, the exact mechanism by which PrkA
mediates-lactam resistance is not well-understood. A consid-
erable number of enzymes and proteins involved in cell wall
metabolism are directly phosphorylated by eSTKs in a variety of
species, with examples including MurC (60), DivIVA/Wag31
(62), GpsB (14), and VraR (27). Such a span of substrates leads
to the conclusion that PrkA (and the PASTAkinases in general)
may play a role in many aspects of cell wall metabolism such as
muropeptide synthesis, PBP function and localization, and the
orchestration of cell elongation and septation. These possibili-
ties are still under investigation.
In conclusion, we have identifiedGSK690693 and other IPAs
as novel inhibitors of the PASTAkinase PrkAwith the potential
for increased selectivity among PASTA kinases. We have
shown that GSK690693 potentiates -lactam activity against
Listeria in broth culture. Furthermore, we have begun to estab-
lish an SARby demonstrating that the alkynol group and nature
of the back pocket in which it is predicted to be bound is poten-
tially important for PASTA kinase inhibition by IPAs. These
studies represent a stepping stone in the development of new
and selective antibiotic therapies that could breathe new life
into an exhausted antibiotic class.
Materials andmethods
Bacterial strains and growth conditions
All bacterial strains used in this study are listed in supple-
mental Table S1. Conditional deletion of prkA (prkA) was
achieved as previously described (34). All L. monocytogenes
strains were grown in brain-heart infusion (BHI) medium at
30 °C in stationary overnight until the strains reached station-
ary phase. Cultures were then back-diluted 1:50 for in vitro
growth experiments. All S. aureus strains were grown in tryptic
soy broth medium at 37 °C shaking overnight until stationary
phase. Cultures were then back-diluted to anA600 of 0.06 for in
vitro growth experiments. Escherichia coli strains XL-1Blue
and Rosetta BL21 were used for subcloning and protein expres-
sion, respectively.When needed, chloramphenicol (Sigma) was
used at 10 g/ml and carbenicillin (Sigma) was used at 100
g/ml. For all broth growth assays, GSK690693 (Selleck Chem-
icals, Houston, TX) was used at a final concentration of 20 M
(2% DMSO) unless otherwise specified in the figure legends.
Library screen
The PKIS1 and Selleck libraries were obtained via the Uni-
versity of Wisconsin Carbone Cancer Center’s Small Molecule
Screening Facility. Overnight cultures were back-diluted 1:50
into fresh BHI medium containing 1 g/ml of ceftriaxone and
either library compounds (final concentration: 10 M in 2%
DMSO) or DMSO (final concentration: 2%). Growth was mea-
sured as an optical density at 600 nm (A600) in 15-min intervals
for 12 h in a 96-well format using an Eon microplate spectro-
photometer or Synergy HT microplate spectrophotometer
Imidazopyridine aminofurazans as PASTA kinase inhibitors
17042 J. Biol. Chem. (2017) 292(41) 17037–17045
(BioTek Instruments, Inc., Winooski, VT) (growth conditions:
37 °C, linear shaking). Each compoundwas screened twice. Per-
cent inhibition was calculated as (1  (ODx/ODCRO))  100,
where ODX is the end pointA600 for a culture treated with both
ceftriaxone and compound X, andODCRO is the end pointA600
for a culture treated with ceftriaxone alone. Compounds that
inhibited growth 3 S.D. greater than the library mean were fur-
ther verified for dose responsiveness and-lactamdependence.
MIC determination
Overnight cultures of L. monocytogenes were back-diluted
1:50 into fresh BHI medium containing 2-fold dilutions of the
antibiotics ampicillin, ceftriaxone, meropenem, tunicamycin,
kanamycin, or vancomycin in the presence or absence of
GSK690693. A600 was measured to monitor growth of the
microdilutions as described above. S. aureus overnight cultures
were back-diluted to anA600 of 0.06 into cation-adjustedMuel-
ler-Hintonmediumcontaining 2-fold dilutions of the antibiotic
ceftriaxone in the presence or absence of GSK690693.A600 was
measured to monitor growth of the microdilutions for 16 h.
MICs were defined as the lowest concentration of antibiotic
required to prevent turbidity in broth visible by eye. Each MIC
experiment was performed at least three times.
Kinase domain protein expression and purification
The prkA and stk1 kinase domains (1–338 and 1–348,
respectively) were subcloned into the expression vector
pGEX-2T as previously described (34). The plasmids were
transformed into E. coli Rosetta BL21 cells, and protein expres-
sion was verified by SDS-PAGE. The bacteria were pelleted by
centrifugation and resuspended in lysis buffer (25 mM Tris, pH
8.0, 150 mMNaCl, 1 mM dithiothreitol, 10 mMMgCl2) contain-
ing 2 g/ml of DNase, 2 g/ml of aprotinin, 1 g/ml of leupep-
tin, and 25 g/ml of phenylmethylsulfonyl fluoride (PMSF).
Cells were lysed by sonication, and cell debris was pelleted by
centrifugation for 20 min. Supernatant was passed through
GS4FF affinity resin columns at 4 °C; columns were then rinsed
with lysis buffer, and the protein eluted with elution buffer (50
mM Tris, pH 8.0, 5 mM NaCl, 3 mM DTT, 20 mM reduced glu-
tathione, 1 mM MgCl2). Eluted protein was then digested over-
night at 4 °C with 1/20 (w/w) thrombin. Digested protein was
passed through a HiPrep Q16 10FF anionic exchange column
(Buffer A: 20mMTris, pH 8.0, 1mMDTT) via an A¨KTApurifier
(GE Healthcare Life Sciences); protein was eluted off the col-
umn with a 0–50% gradient of Buffer B (20 mM Tris, pH 8.0, 1
mM DTT, 1 M NaCl). Target fractions were then combined and
passed through GS4FF affinity columns as described above.
The flow-through was concentrated via spin columns and
passed through a Sephadex 75 size exclusion column on the
A¨KTA purifier (Running Buffer: 10 mM Tris, pH 8.0, 150 mM
NaCl, 1 mM DTT, 10 mM MgCl2). Fractions were tested for
purity by SDS-PAGE and combined. For Stk1 purification,
MgCl2 was replaced with MnCl2 throughout.
Generation of kinasemutants
All plasmids generated in this study are listed in supplemen-
tary Table S2. To generate the Stk1-F150T mutant, plasmid
pGEX-2T-Stk1 was digested with BamHI and KpnI (New
England Biolabs) to remove the wild-type N-terminal Stk1
sequence. A gBlock gene fragment (Integrated DNA Technol-
ogies) consisting of the excised N-terminal sequence with a
F150T (T1404A, T1405C) mutation was ligated into the
digested plasmid to yield pGEX-2T-Stk1 F150T. To generate
the PrkA T151F mutant, a similar process was performed on
thepGEX-2T-PrkAplasmid,utilizingBamHIandEcoRI restric-
tion sites and a gBlock gene fragment with a T151F (A451T,
C452T, A453T) mutation to yield pGEX-2T-PrkA T151F.
Finally, to generate the Stk1 S62A/M73V/L85I triple mutant, a
similar process was performed on the pGEX-2T-Stk1 plasmid,
utilizing BamHI and KpnI restriction sites and a gBlock gene
fragmentwith S62A (T187A),M73V (A217G,G219T), andL85I
(T253A, A255T) mutations to yield pGEX-2T-Stk1 S62A/
M73V/L85I. All mutant constructs were validated by sequenc-
ing. Mutant constructs were transformed into E. coli Rosetta
BL21 cells and protein expression and purification were per-
formed in the same fashion as the wild-type constructs.
Generation ofstk1mutant
Regions 1000 bp in size directly upstream and downstream
were amplified with primer pairs JDS88/BK34 and BK35/
JDS89, respectively (supplemental Table S3). These regions
were fused by “splice by overlap” PCR and ligated into the plas-
mid pJB38 utilizing the SacI and XmaI restriction sites to yield
pJB38-stk1. The construct was electroporated into the
S. aureus strain RN4220 then transduced into LAC by phage
transduction. Deletion of the stk1 gene was then performed by
pJB38-mediated allelic exchange as described by Bose et al.
(63). Successful deletion of stk1 was validated by PCR.
Kinase-Glo assay
The kinase assays were performed using the KinaseGlo re-
agent from Promega. All reactions were done in 50 l volume.
The buffer used for all kinase assays was 10 mM Tris-HCl, pH
7.4, 150mMNaCl, 1 mMDTT, and 1mMMgCl2. Drugs in 5mM
DMSOwere diluted in kinase buffer to 1/2 the final concentra-
tion using a serial dilution from 20 to 0 M. The final DMSO
concentration in the reactionswas nomore than 0.4%. PrkA(1–
338) was added to the drugs to a final concentration of 2.0 M
and allowed to incubate for 10 min at 37 °C. ATP and MBP
(Novatein Biosciences, Woburn, MA) were added for a final
concentration of 100 and 40 M, respectively, initializing the
reaction. After a half-hour incubation, the reactionwas stopped
by the addition of 50 l of KinaseGlo reagent, and the signal
was allowed to stabilize for 10min at room temperature per the
product manual. The plate was read using luminescence detec-
tion on a Synergy HT detector (BioTek) and the data were col-
lected using the Gen5 2.0 software (BioTek). The data were
transformed to log scale and non-linear regression was per-
formed in PRISM using the variable slope 4-parameter model
for enzyme inhibition to determine IC50.
In vitro protein phosphorylation
2Mkinase domain, 10MMBP (Novatein Biosciences), and
various concentrations of kinase inhibitors were incubated on
ice for 10 min, then added to a mixture of 10 mM Tris, pH 7.4,
150 mM NaCl, 1 mM MgCl2 (50 M MnCl2 for Stk1 and its
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mutants), 50MATP, and 1Ci of [-32P]ATP. Reactionswere
incubated at 37 °C for 1 h and terminated by the addition of 6
SDS loading buffer. Samples were run on an SDS-PAGE gel
then fixed for 2 h in fixation solution (40% methanol, 5% glyc-
erol, 10% glacial acetic acid). Fixed gels were dried for 1 h and
blots were visualized by autoradiography.
In silicomodeling
The primary sequences of the PrkA and Stk1 kinase domains
(residues 1–270)were threaded onto the crystal structure of the
kinase domain of PknB from M. tuberculosis (PDB ID 1O6Y)
using the Phyre2 server’s one-to-one threading (64). Hydrogen
atoms and Gasteiger-Huckel charges were added, and energy
minimization was performed using SYBYL-X1.2 (65). The
structure of GSK690693 was downloaded as a MOL2 file from
the ZINC database (66). Hydrogen atoms and Gasteiger-
Huckel charges were added, and energy minimization was per-
formed using SYBYL-X1.2. GSK690693was docked into a 66
66  66 unit grid encompassing the kinases’ active site clefts
using the docking program Autodock’s Lamarckian genetic
algorithm (49). Models were visualized using PyMOL (61). The
reference crystal structure of GSK690693 bound to human
AKT (PDB ID 3d0e) was directly downloaded from the PDB
and visualized in PyMOL without modifications.
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